Table 1.
Patient demographics and clinical characteristics.
| Characteristics | Total (N = 29) No. of patients (%) |
|---|---|
| Age at enrollment, years | |
| Median [range] | 57 [39-76] |
| Gender | |
| Male | 14 (48.3) |
| Female | 15 (51.7) |
| Treatment line at the time of sampling | |
| FOLFIRI + bevacizumab | 15 (51.7) |
| FOLFIRI + ramucirumab | 10 (34.5) |
| FOLFOX + bevacizumab | 4 (13.8) |
| Primary site | |
| Right-sided colon | 13 (44.8) |
| Left-sided colon | 16 (55.2) |
| Resection of primary tumor | |
| Yes | 18 (62.1) |
| No | 11 (37.9) |
| Metastatic site | |
| Single organ | 8 (27.6) |
| Multi-organ | 21 (72.4) |
| Liver | 27 (93.1) |
| Lung | 14 (48.3) |
| Peritoneal | 9 (31.0) |
| Lymph node | 7 (24.1) |
| Other | 3 (10.3) |
| RAS status in tissue | |
| Wild type | 10 (34.5) |
| Mutant | 19 (65.5) |
| Prior Chemotherapy regimen | |
| Anti-VEGF antibody | 21 (72.4) |
| Anti-EGFR antibody | 6 (20.7) |
| Cytotoxic drug(s) only | 2 (6.9) |
| Tumor markers (at initiation of second-line chemotherapy) | |
| CEA median, [range] | 48.6 [3.4–1119.9] |
| CA19-9 median, [range] | 62.1 [2.0–8017.7] |
FOLFIRI:a combination of leucovorin and fluorouracil with irinotecan.
VEGF:vascular endothelial growth factor.
FOLFOX:a combination of leucovorin and fluorouracil with oxaliplatin.
EGFR:epidermal growth factor receptor.
5-FU:5-fluorouracil.
LV:leucovorin.
RAS:rat sarcoma viral oncogene homolog.
CEA:carcinoembryonic antigen.
CA19-9:carbohydrate antigen 19-9.